Meninges

Grant for High-Risk, High-Impact Brain Cancer Research Awarded to Ivy Center Investigator

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Meninges, III, Meningioma, Engineering, Protein, Doctor of Philosophy, American Brain Tumor Association, Faculty, Research, Biology, Glioblastoma, Hedera, Brain, II, Assistant, Ribociclib, Time, Drug development, Neoplasm, Barrow Neurological Institute, Cell, Patient, Growth, Breast cancer, Associate, Cyclin-dependent kinase 4, Arizona State University, MD, FDA, Medical imaging, Pharmaceutical industry

Dr. Tien is a rising star in translational brain cancer research and PK/PD-triggered early-phase clinical trials.

Key Points: 
  • Dr. Tien is a rising star in translational brain cancer research and PK/PD-triggered early-phase clinical trials.
  • This funding will allow us to advance the translational work were doing at the Ivy Brain Tumor Center and directly impact patients, said Dr. Tien.
  • Ivy Brain Tumor Center at the Barrow Neurological Institute in Phoenix, AZ is a non-profit translational research program that employs a bold, early-phase clinical trials strategy to identify new treatments for aggressive brain tumors, including glioblastoma.
  • Follow the Ivy Brain Tumor Center on Facebook , Instagram , Twitter and LinkedIn .

Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial

Retrieved on: 
Thursday, June 16, 2022
Gy, MFD, Spinal cord, Lymphatic system, Cancer, Review, FDA, NDA, Safety, Ayub Ommaya, Perception, MTD, Company, Brain, U.S. Securities and Exchange Commission, Research, Fast Track, New Drug Application, PSTV, Disease, DNA, Liposome, Physician, Nasdaq, Radiation, SVP, Incidence, LM, Patient, White Light Rock & Roll Review, Toxic leukoencephalopathy, Communication, Neoplasm, Toxicity, Membrane, Accelerated approval (FDA), Therapy, Priority review, GLOBE, Meninges, Index (publishing), Pharmaceutical industry, Medical imaging

AUSTIN, Texas, June 16, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the completion of enrollment in the first cohort of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM).

Key Points: 
  • We are pleased with initial response to the ReSPECT-LM trial by patients and physicians and the very early promising drug performance, said Norman LaFrance, M.D., Chief Medical Officer and SVP of Plus Therapeutics.
  • We intend to provide enrollment and complete clinical updates in the third quarter of 2022.
  • The ReSPECT-LM trial ( NCT05034497 ) is a multicenter, sequential cohort, open-label, single dose, dose escalation Phase 1/2a study using a modified Fibonacci 3+3 study design.
  • The primary endpoints of the study are the incidence and severity of adverse events/serious adverse events and dose limiting toxicities.

Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases

Retrieved on: 
Tuesday, March 22, 2022
Spinal cord, Company, Cancer, Therapy, Life, Meninges, Glioblastoma, Fast Track, DNA, LM, Principal investigator, Toxicity, White Light Rock & Roll Review, MFD, Central nervous system, MTD, CNS, Research, Gastrointestinal cancer, Liposome, Perception, Food and Drug Administration, Neoplasm, Incidence, Ayub Ommaya, Food, Neuro-Oncology (journal), Membrane, Communication, University of Texas Southwestern Medical Center, Lymphatic system, Index (publishing), SVP, New Drug Application, Accelerated approval (FDA), Safety, Review, Assistant, Priority review, Nasdaq, U.S. Securities and Exchange Commission, Brain, GLOBE, Melanoma, NDA, Toxic leukoencephalopathy, Gy, PSTV, FDA, Breast cancer, Lung cancer, University, Patient, Disease, Prognosis, Radiation, Pharmaceutical industry, Medical imaging

AUSTIN, Texas, March 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the first patient has been dosed in the ReSPECT-LM Phase 1/2a dose escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of patients with leptomeningeal metastases (LM).

Key Points: 
  • The investigational drug, 186RNL, is a proprietary nanoscale compound with a unique chelated radioisotope that is administered locally as a single dose via a conventional Ommaya reservoir.
  • Initiating treatment in LM patients with 186RNL marks an important milestone for Plus Therapeutics and potentially for the LM patient population.
  • The ReSPECT-LM trial ( NCT05034497 ) is a multicenter, sequential cohort, open-label, single dose, dose escalation Phase 1/2a study using a modified Fibonacci 3+3 study design.
  • The primary endpoints of the study are the incidence and severity of adverse events/serious adverse events and dose limiting toxicities.

Global Blood Brain Barrier Technologies Market Report 2021-2028: Large Number of Product Approvals and Launches & Nanoparticles for Brain Drug Delivery - ResearchAndMarkets.com

Retrieved on: 
Friday, February 4, 2022
Other Health, Pharmaceutical, Mental Health, Medical Devices, Technology, Science, Nanotechnology, Biotechnology, Medical Supplies, Other Technology, Other Science, Health, Growth, Lists of diseases, Alzheimer's disease, Traffic barrier, Alzheimer's Association, Epilepsy, Cell, Neurodegeneration, Dementia, Seizure, RMT, Injury, Korea Disease Control and Prevention Agency, Parkinson's disease, Brain, BBB, Cerebral palsy, Death, Technology, Center, COVID-19, CAGR, Foundation, WHO, Prevalence, CDC, Cerebrospinal fluid, Autism, World Health Organization, Blood, Neurological disorder, Association, World, Bispecific monoclonal antibody, Parkinson, Hunter syndrome, Permeability, Disability, Meninges, Multiple sclerosis, Vaccine, Pharmaceutical industry, Medical imaging, Residential care

The "Blood Brain Barrier Technologies Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Brain Barrier Technologies Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Blood brain barrier is another protective element present between the brain's blood vessels, and the cells and other components that together make up brain tissue.
  • The blood brain barrier protects the brain against disease-causing pathogens/toxins that may be present in the blood.
  • Based on application, the blood brain barrier technologies market is segmented into Alzheimer's disease, epilepsy, Parkinson's disease, multiple sclerosis, Hunter's syndrome, brain cancer, and others.

New Preclinical Data at SITC 2021 Show Broad Potential Utility of Codiak’s Engineered Exosomes

Retrieved on: 
Friday, November 12, 2021
Cancer, Breast, Therapeutic index, Security (finance), LMD, Tumor microenvironment, Phenotype, Therapy, Lung, Biology, Cell, Kaposi's sarcoma, Peptide, NHP, Glioblastoma, Pharmacology, Thyroid cancer, CTCL, STAT6, U.S. Securities and Exchange Commission, GLOBE, Tropism, HCC, Patient, Macrophage, Private Securities Litigation Reform Act, ASO, Exosome, Wilms' tumor, Adenocarcinoma, Liver, Society, Publication, Hepatocellular carcinoma, Protein, APC, Glioma, Immunotherapy, Central nervous system, PTGFRN, SITC, Uveal melanoma, Engineering, Infection, Ovarian cancer, Merkel-cell carcinoma, TGI, CNS, Neoplasm, Toxicity, Meninges, Nasdaq, Tumor-associated macrophage, Melanoma, IND, Pharmaceutical industry, Vaccine, Fine chemical, Medical imaging

CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that new preclinical data from programs using its engEx™ Platform will be presented this week at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2021). Results from three preclinical studies highlight the potential for engineered exosomes to elicit a therapeutic immunological response with cancers and targets that have been historically difficult to drug, presenting new potential applications for the company’s clinical and preclinical candidates.

Key Points: 
  • Results from three preclinical studies highlight the potential for engineered exosomes to elicit a therapeutic immunological response with cancers and targets that have been historically difficult to drug, presenting new potential applications for the companys clinical and preclinical candidates.
  • Codiak has two programs currently in clinical development, exoIL-12 and exoSTING, for the treatment of lymphoid and solid tumors, respectively.
  • Both exoSTING and exoIL-12, when administered as a monotherapy, elicit potent and selective immune responses in preclinical tumor models.
  • Preclinical data presented at SITC 2021 demonstrate the ability of exoASO-STAT6 as a single agent to effectively target and reprogram immunosuppressive macrophages to a pro-inflammatory phenotype and to generate robust anti-tumor activity.

Plus Therapeutics Receives FDA Fast Track Designation for 186RNL Targeted Radiotherapeutic for Leptomeningeal Metastases

Retrieved on: 
Tuesday, November 9, 2021
NDA, Safety, Brain, Membrane, Cancer, Lung cancer, Biomarker, Priority review, Therapy, Spinal cord, Neoplasm, Lincoln Park, Toxic leukoencephalopathy, Melanoma, Radiation, Disease, Food, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Regulation, Perception, Incidence, Company, New Drug Application, GLOBE, Accelerated approval (FDA), U.S. Securities and Exchange Commission, Breast cancer, PSTV, Glioma, Review, Communication, LM, Survival, Central nervous system, Meninges, Nasdaq, White Light Rock & Roll Review, Patient, Marketing, IND, Intellectual property, Pharmaceutical industry

The incidence of LM is rising and represents a rapidly progressing and fatal complication of several cancer types, said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.

Key Points: 
  • The incidence of LM is rising and represents a rapidly progressing and fatal complication of several cancer types, said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • Based on our clinical experience with 186RNL in glioma and preclinical studies in LM models, we are optimistic that 186RNL may have a therapeutic role in management of this increasingly common cancer.
  • NDA review usually does not begin until the drug company has submitted the entire application to the FDA.
  • The primary endpoint of the study is the incidence and severity of adverse events/serious adverse events and dose limiting toxicities.

Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Leptomeningeal Metastases

Retrieved on: 
Tuesday, October 19, 2021
Membrane, Gy, Toxicity, IND, Regulation, University, Perception, Neurosurgery, Cancer, U.S. Securities and Exchange Commission, Lung cancer, Metastasis, Incidence, Spinal cord, Melanoma, Breast cancer, Disease, Central nervous system, Lincoln Park, Research, Glioblastoma, Intellectual property, Neoplasm, University of Texas at Austin, PSTV, FDA, Nasdaq, Meninges, Therapy, Brain, GLOBE, Neurology, Survival, LM, Patient, Radiation, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Liposome, Marketing, Safety, C6, Company, Pharmaceutical industry

AUSTIN, Texas, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM). The Company expects to initiate patient accrual in a Phase 1 dose escalation trial of 186RNL (ReSPECT-LM) in the fourth quarter of 2021.

Key Points: 
  • The Company expects to initiate patient accrual in a Phase 1 dose escalation trial of 186RNL (ReSPECT-LM) in the fourth quarter of 2021.
  • The ReSPECT-LM trial is a multicenter, sequential cohort, open-label, single dose, dose escalation Phase 1 study.
  • The primary endpoint of the study is the incidence and severity of adverse events/serious adverse events and dose limiting toxicities.
  • Leptomeningeal metastasis is a neurologically devastating and fatal complication of cancer, said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.

Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas

Retrieved on: 
Thursday, October 7, 2021
NASDAQ, Twitter, Automation, Bias, Algorithm, Priority review, Biology, SALT, Accelerated approval (FDA), Meningioma, Drug discovery, Engineering, Fast Track, Machine learning, Food, Central nervous system, NF2, Radiation, LinkedIn, Meninges, FDA, Neurofibromatosis, Review, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Autosome, Recursion, Medicine, Fast track (FDA), Patient, HDAC, Chemistry, Pharmaceutical industry

REC-2282 is a potentially first-in-class, orally bioavailable, CNS-penetrant small molecule HDAC inhibitor being developed for the treatment of NF2-mutated meningiomas.

Key Points: 
  • REC-2282 is a potentially first-in-class, orally bioavailable, CNS-penetrant small molecule HDAC inhibitor being developed for the treatment of NF2-mutated meningiomas.
  • The FDA's Fast Track designation was established to expedite the review of investigational drugs to treat serious conditions and address unmet medical needs by enabling important drugs to get to patients earlier if approved.
  • Fast Track designation can lead to more frequent interactions with the FDA, as well as Accelerated Approval and/or Priority Review eligibility if certain criteria are met.
  • Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering.

EpiFaith®, The Innovative Epidural Safeguard, Now Arrives in APAC Hospitals

Retrieved on: 
Tuesday, September 22, 2020
General Health, Health, Medical Supplies, Medical devices, Clinical medicine, Medicine, Regional anesthesia, Childbirth, Epidural administration, Health care, Post-dural-puncture headache, Meninges, Dura mater

Following its U.S. and European launch announcement in 2019, the company has been devoted to supplying EpiFaith, the visualized safety solution for epidural locating, to Western hospitals.

Key Points: 
  • Following its U.S. and European launch announcement in 2019, the company has been devoted to supplying EpiFaith, the visualized safety solution for epidural locating, to Western hospitals.
  • At the same time, it has kept working on getting regulatory approval in its hometown market, the Asia Pacific region.
  • But the truth is it's not, PDPH and CNS injury in epidural is still a big problem, and, unfortunately, some colleagues chose to neglect the risk.
  • We are happy that the product has finally been approved and launched here to eliminate the accidental dural puncture.

EpiFaith®, The Innovative Epidural Safeguard, Now Arrives in APAC Hospitals

Retrieved on: 
Monday, September 21, 2020
Medical devices, Medical Supplies, Women, Baby, Maternity, Biotechnology, Other Health, Health, Consumer, General Health, Clinical medicine, Medicine, Regional anesthesia, Childbirth, Epidural administration, Health care, Post-dural-puncture headache, Meninges, Dura mater

Following its U.S. and European launch announcement in 2019, the company has been devoted to supplying EpiFaith, the visualized safety solution for epidural locating, to Western hospitals.

Key Points: 
  • Following its U.S. and European launch announcement in 2019, the company has been devoted to supplying EpiFaith, the visualized safety solution for epidural locating, to Western hospitals.
  • At the same time, it has kept working on getting regulatory approval in its hometown market, the Asia Pacific region.
  • But the truth is it's not, PDPH and CNS injury in epidural is still a big problem, and, unfortunately, some colleagues chose to neglect the risk.
  • We are happy that the product has finally been approved and launched here to eliminate the accidental dural puncture.